Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04895761
Title Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Providence Health & Services
Indications

Her2-receptor negative breast cancer

Therapies

DPX-Survivac + Letrozole

Cyclophosphamide + DPX-Survivac + Letrozole

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.